Heska Corp (NASDAQ:HSKA) has earned an average recommendation of “Hold” from the eight ratings firms that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $109.33.
Several brokerages have weighed in on HSKA. BidaskClub downgraded Heska from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Zacks Investment Research downgraded Heska from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Aegis reiterated a “buy” rating on shares of Heska in a report on Tuesday, December 19th. Raymond James Financial reiterated a “buy” rating on shares of Heska in a report on Monday, December 4th. Finally, B. Riley cut their price target on Heska from $96.50 to $93.00 and set a “neutral” rating for the company in a report on Friday, November 3rd.
In other news, insider Michael J. Mcginley sold 7,826 shares of the company’s stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $87.14, for a total transaction of $681,957.64. Following the completion of the sale, the insider now directly owns 106,771 shares in the company, valued at approximately $9,304,024.94. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 14.70% of the company’s stock.
Shares of Heska (NASDAQ:HSKA) traded down $0.24 on Friday, reaching $79.80. The company’s stock had a trading volume of 46,683 shares, compared to its average volume of 78,688. The firm has a market cap of $574.91, a P/E ratio of 42.00, a PEG ratio of 2.11 and a beta of 0.74. Heska has a 52 week low of $75.21 and a 52 week high of $115.00.
Heska (NASDAQ:HSKA) last issued its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.40 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.03. The company had revenue of $31.40 million during the quarter, compared to the consensus estimate of $36.10 million. Heska had a return on equity of 15.35% and a net margin of 10.67%. Heska’s revenue was down 6.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.45 EPS. analysts expect that Heska will post 2.03 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Heska Corp (HSKA) Receives Consensus Rating of “Hold” from Analysts” was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3147758/heska-corp-hska-receives-consensus-rating-of-hold-from-analysts.html.
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.